| Patient | Alan Turing |
|---|---|
| Date of birth | 1985-06-23 |
| Identifiers | MRN HR-ML007-SYN; SSN (made up) 000-07-6290 |
| Document date | 2026-04-14 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Bilateral tender gynecomastia, suppressed testosterone and gonadotropins, and low libido in a 40-year-old man three weeks after the last of a year of high-dose estrogen injections given without his free consent. Please confirm the cause, advise what further tests are needed, and advise on recovery, testosterone therapy, bone health, and surgery. [S]
Urgency: Soon, within two weeks. [S]
Questions for the consultant:
For about a year, until three weeks ago, he received high-dose estrogen injections abroad as a condition imposed after a criminal conviction for a consensual relationship with another adult man; he did not freely consent and wants no further doses. Over that year his breasts enlarged and became tender, his libido and erections disappeared, and his running fell off. Examination today shows firm, tender, symmetric glandular tissue about 4 cm across behind each nipple, with no discrete mass, skin change, discharge, or axillary nodes, and soft, slightly small testes without masses. Total testosterone 112 ng/dL, estradiol 148 pg/mL, LH 0.3 and FSH 0.4 mIU/mL, prolactin 21.6 ng/mL, SHBG 88 nmol/L, hCG beta 1 mIU/mL, AFP 2.6 ng/mL, liver tests, creatinine, and TSH normal, hemoglobin 13.0 g/dL, and 25-hydroxyvitamin D 22 ng/mL. He takes no other medicine, anabolic steroid, or supplement, and drinks two or three drinks a week. He is also being treated here for a moderate depressive episode, with psychotherapy; PHQ-9 15 with no suicidal ideation. Cholecalciferol 1,000 units daily was started today. He is a long-distance runner and a gay man; he asks that every test and treatment be explained to him first [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-14 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | active | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 31 March 1952 | Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecency | D (CLM-0003, CLM-0004) |
| 1952 | Breast growth attributed to the hormone treatment, which he is known to have mentioned once | D (CLM-0005) |
| November 1952 | Decided to see a psychiatrist again and began Jungian analysis | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-14 | Body height | 178 | cm | S |
| 2026-04-14 | Body weight | 71.4 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 64 | /min | S |
| 2026-04-14 | Respiratory rate | 14 | /min | S |
| 2026-04-14 | Body temperature | 36.6 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 15 | {score} | S | ||
| 2026-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-04-14 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-04-14 | Testosterone [Mass/volume] in Serum or Plasma | 112 | ng/dL | 264-916 ng/dL | Low | S |
| 2026-04-14 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 148 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 2026-04-14 | Lutropin [Units/volume] in Serum or Plasma | 0.3 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
| 2026-04-14 | Follitropin [Units/volume] in Serum or Plasma | 0.4 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Low | S |
| 2026-04-14 | Sex hormone binding globulin [Moles/volume] in Serum or Plasma | 88 | nmol/L | 16.5-55.9 nmol/L | High | S |
| 2026-04-14 | Prolactin [Mass/volume] in Serum or Plasma | 21.6 | ng/mL | 4-15.2 ng/mL | High | S |
| 2026-04-14 | Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma | 1 | m[IU]/mL | <=3 m[IU]/mL | Normal | S |
| 2026-04-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | <=8.3 ng/mL | Normal | S |
| 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 2026-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-14 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-04-14 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-04-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |